PPLPHARMA Piramal Pharma Q4 FY26 results (Jan–Mar 2026) and concall
Piramal Pharma navigated a transitional FY26, experiencing a year-on-year decline in reported revenues and EBITDA due to external headwinds and inventory de-stocking, alongside a significant intangible write-down. However, the underlying business showed modest growth, driven by strong H2 CDMO order inflows, the Kenalog acquisition, and robust consumer healthcare performance. The company anticipates a return to healthy early-to-mid-teen revenue growth in FY27, with EBITDA and PAT growing faster, despite an elevated debt-to-EBITDA ratio and projected continued quarterly volatility in CDMO.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 0.1%, net profit down 105.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,242 | 2,204 | 2,754 | 1,934 | 2,044 −9% | 2,140 −3% | 2,752 −0% |
| EBITDA | 342 | 338 | 561 | 107 | 159 −54% | 196 −42% | 461 −18% |
| Net profit | 23 | 4 | 154 | -82 | -99 −530% | -136 −3500% | -9 −106% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
